See the DrugPatentWatch profile for Breyanzi
Who holds the Breyanzi (lisocabtagene maraleucel) patents, and what are they protecting?
Breyanzi is a CAR T-cell therapy. Patent coverage for a product like Breyanzi typically protects parts of the technology pipeline rather than the “medicine” alone, such as:
- the genetic construct used to redirect T cells (the CAR design),
- manufacturing steps used to produce the patient’s modified cells,
- specific dosing/regimen elements tied to clinical use.
Your ability to find “the” Breyanzi patent depends on which aspect you mean (the CAR construct, the manufacturing process, or clinical use), because different claims are held in different patent families.
When do Breyanzi patents expire?
Patent expiration is not a single date for Breyanzi. It depends on:
- the filing dates in each patent family,
- whether any patents are extended via regulatory exclusivity mechanisms in the relevant country,
- country-by-country prosecution outcomes.
Because you asked generally for “Breyanzi patent,” the key point is that there isn’t one universal “expiration date.” The earliest and latest expirations can differ across families, and exclusivity timing can also differ from patent timing.
Can biosimilars or CAR-T “alternatives” launch before Breyanzi’s patents expire?
For advanced biologics like CAR T therapies, the closest real-world question is usually whether competitors can launch products that avoid infringing key claims. Even if a product is clinically similar, infringement risk depends on claim coverage and design-around:
- If another company uses different CAR components or manufacturing steps, it may avoid certain claims.
- If it uses technology covered by Breyanzi’s patents, it may face infringement allegations or require licensing.
What happens if a company challenges Breyanzi’s patent?
Patent disputes in this area typically play out through:
- infringement litigation (arguing the competitor’s product/manufacturing falls within Breyanzi claims),
- validity challenges (arguing claims are not novel or are obvious),
- settlement agreements that can delay or shape entry.
The practical outcome is often an entry timeline that turns on which patents are asserted and which claims survive.
How do you look up the exact Breyanzi patent(s) you need?
If you want the specific patent numbers and assignees, the most reliable approach is to search by:
- the product name (Breyanzi),
- the active ingredient name (lisocabtagene maraleucel),
- assignees that own the IP for the therapy,
- patent family members in key jurisdictions (US, EP, JP, CN, etc.).
To narrow this accurately, tell me which of these you’re looking for:
- a specific country’s patents (US or EU, for example),
- the earliest expiration date,
- patents covering the CAR construct vs. manufacturing vs. clinical claims,
- or a particular company you suspect is competing with Breyanzi.
What’s the fastest way to get the correct answer for your use case?
Reply with one detail and I’ll tailor the patent answer:
1) Which jurisdiction (US, EU, UK, Japan, etc.)?
2) Are you looking for “earliest expiry,” “list of key patents,” or “is someone launching a competing CAR-T?”